Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in NSCLC with EGFR or HER2 Exon 20 Insertion Mutations
NCT04063462Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of pyrotinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04063462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063462.